Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...

Novartis, meanwhile, is also looking to muscle in on the adjuvant setting with the NATALEE trial of Kisqali, due to generate results later this year. The CDK 4/6 drug made $1.2 billion in sales ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

At Novartis, our continued success depends on our ability to proactively detect and manage risk. Therefore, risk management is an integral element of our Ethics, Risk and Compliance program. As part ...

Amit Shah vows anti-conversion law in Maharashtra, opposition caste census Union Home Minister Amit Shah, during the release of BJP's election manifesto in Mumbai, promised a stringent anti ...

After hours: 7 November at 6:28 pm GMT-5 ...

Foreign leaders have rushed to ingratiate themselves with Donald J. Trump in recent days, nervously recalling the clashes, insults and feuds of his first presidency. By Mark LandlerMatina Stevis ...

Nov. 7, 2024 — Plastic pollution exacerbates the impacts of all planetary boundaries, including climate change, ocean acidification and biodiversity loss, a new paper shows. Ahead of the final ...